Determination of potentially drug-drug interaction in oncology patients

Basit Öğe Kaydı
dc.contributor.authorAbunahlah, Nibal
dc.contributor.authorSancar, M.
dc.contributor.authorDane, F.
dc.contributor.authorÖzyavuz, M. K.
dc.contributor.authorİzzettin, F.
dc.date.accessioned2021-05-15T12:37:12Z
dc.date.available2021-05-15T12:37:12Z
dc.date.issued2016
dc.departmentEczacılık Fakültesien_US
dc.description.abstractBackground International guidelines are tools enabling physicians to incorporate the latest evidence based clinical information into practice. Objective This study aimed to evaluate the impact of antiemetic guidelines adherence on the incidence of chemotherapy-induced nausea and vomiting (CINV) and patient quality of life. Setting Marmara University Pendik Training and Research Hospital chemotherapy unit, Istanbul, Turkey. Method The study included 100 chemotherapy naive patients. Antiemetic prescribing patterns and their consistency with MASCC/ESMO 2014 guidelines were assessed. Patients recorded incidences of vomiting in a daily dairy and described their nausea using a 7-item Likert Scale. The incidence of CINV was recorded over five days. To assess the patient’s quality of life, a modified Turkish version of the Functional Living Index-Emesis (FLIE) questionnaire was administered before and after receiving chemotherapy. A questionnaire on the existence and severity of side effects was developed and administered. Main outcome measures Incidence of side effects on CINV and quality of life according to the FLIE. Results The primary outcome revealed differences in complete control (no emetic episodes, rescue therapy or nausea), FLIE scores and side effects. Guidelines consistency was observed more with acute (A) than with delayed (D) prevention of CINV, with significant differences in complete control between the guideline adherent group (GAG) and the guideline nonadherent group (GNG). Significant differences in the FLIE score were noticed between GAG(D) and GNG(D), and GNG(D) had a higher incidence of diarrhoea, headache, swallowing difficulties and darkcoloured stool. Conclusion Consistency with guidelines resulted in significant reduction in the incidence of both cute and delayed CINV and other side effects, and with improvement of the patient quality of life.en_US
dc.identifier.endpage504en_US
dc.identifier.issn2210-7703
dc.identifier.issn2210-7711
dc.identifier.issue2en_US
dc.identifier.startpage504en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/495
dc.identifier.volume38en_US
dc.identifier.wosWOS:000374326900123
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.institutionauthorAbunahlah, Nibal
dc.language.isoen
dc.publisherSpringeren_US
dc.relation.ispartofInternational Journal of Clinical Pharmacy
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDrug Interactionen_US
dc.subjectOncologyen_US
dc.subjectClinical Pharmacisten_US
dc.subjectChemotherapyen_US
dc.titleDetermination of potentially drug-drug interaction in oncology patients
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu